AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 82 min read$MGNX

MACROGENICS INC (MGNX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. mgnx-20260701 0001125345 FALSE 0001125345 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

Original reporting
SEC EDGAR 8-K
Published Jul 8, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 8, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$MGNX
Neutral
medium confidence
Mentioned
$MGNX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MGNXNeutralLow
01

Why it matters

The only disclosed event is the resignation notice, effective September 1, 2026, with an explicit statement that it was not due to disagreements or company operational issues.

02

Market read

This is a governance update without new financial guidance, clinical data, or strategic transaction details.

03

What to watch

Traders may want to check whether Ferrante served on key committees (audit, compensation, nominating) and whether her replacement is announced in future filings.

Relevance 6/10Novelty 3/10Timing: after-hours, following the July 1 resignation notice and July 8 8-K filing

Background

The filing is an SEC Form 8-K under Item 5.02 for director/officer departure and related compensatory arrangements, dated from a July 1 notice.

Company-level read

Ticker impact

$MGNXNeutralMedium confidence
Context

MacroGenics disclosed Karen Ferrante’s resignation from the board, effective September 1, 2026, citing personal reasons.

Expected impact

Likely limited near-term impact unless investors later connect the departure to strategy, leadership, or committee changes.

Evidence & confidence

The 8-K is a primary-source executive/director departure notice with no disagreement with the company and no additional financial or strategic details.

Market effects

Sector

Minimal, as it is company-specific governance news with no sector-wide regulatory or clinical read-across.

Regional

None indicated; US-listed biotech governance update only.

Global

None indicated; no international operations or cross-border transaction details.

Counterpoint

What could challenge this read

Even with “personal reasons,” board departures can precede committee reshuffles or strategic pivots that may surface later in proxy materials.

Key entities

  • Director
    Karen Ferrante, M.D.

    Board member who provided notice of resignation effective September 1, 2026, for personal reasons.

  • Issuer
    MacroGenics, Inc.

    Company filing the 8-K reporting the director resignation under Item 5.02.

Read at source← All news

Related articles

OCT 23
$MGNXMedAI 8/10

MacroGenics reports phase 1 data for MGC026 in solid tumors

MacroGenics Inc. (MGNX) reported phase 1 trial data for MGC026, an antibody-drug conjugate targeting B7-H3, in advanced solid tumors. 85 patients were enrolled, with 29% response rate in dose-escalation and 27% in head and neck cancer cohort. Grade 3+ adverse events occurred in 51% of patients, with no grade 5 events. The company plans further trials with pembrolizumab in 2027.

investing.com2 min
OCT 23
$MGNXMedAI 8/10

Tumors shrank in 6 of 22 patients with head and neck cancer; 2 responses to the experimental drug were unconfirmed.

MacroGenics (MGNX) reported positive interim Phase 1 data for MGC026, its B7-H3-directed antibody-drug conjugate, showing a 27% overall response rate in 22 heavily pretreated SCCHN patients. The drug demonstrated manageable safety and tolerability. The company plans to initiate a front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumab in early 2027. Data were presented at the ESMO 2026 Congress.

stocktitan.net2 min
AUG 13
$MGNXMed

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position • Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately

SEC EDGAR 8-K6 min
AUG 11
$MGNXMed

MacroGenics stock rises on $10M Gilead option exercise

MacroGenics (NASDAQ:MGNX) shares rose 4.3% after hours after Gilead Sciences exercised an option on a preclinical bispecific program under their 2022 collaboration, triggering a $10 million payment. Gilead holds an exclusive license using MacroGenics’ TRIDENT platform targeting two undisclosed solid tumor targets. MacroGenics may receive up to about $1.6 billion more in milestones and royalties.

investing.com2 min
JUL 7
$MGNXMed

MACROGENICS INC (MGNX): Completion of Acquisition or Disposition of Assets

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 3 exhibit99-2proforma.htm EX-99.2 Document Exhibit 99.2 MACROGENICS, INC. UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and

SEC EDGAR 8-K4 min